HC Wainwright Issues Optimistic Estimate for TPST Earnings

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Research analysts at HC Wainwright lifted their FY2026 earnings estimates for Tempest Therapeutics in a report issued on Tuesday, March 31st. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($1.34) for the year, up from their prior forecast of ($2.76). The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ FY2027 earnings at ($1.21) EPS and FY2028 earnings at ($0.89) EPS.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.62) earnings per share for the quarter, meeting the consensus estimate of ($0.62).

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempest Therapeutics in a research note on Monday, December 29th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $12.50.

Tempest Therapeutics Price Performance

Tempest Therapeutics stock opened at $1.59 on Friday. The business has a 50 day simple moving average of $2.25 and a 200 day simple moving average of $5.04. The company has a market capitalization of $22.80 million, a PE ratio of -0.24 and a beta of -2.00. Tempest Therapeutics has a one year low of $1.50 and a one year high of $12.23.

Institutional Investors Weigh In On Tempest Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TPST. Vanguard Group Inc. boosted its stake in Tempest Therapeutics by 20.8% in the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after purchasing an additional 27,952 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Tempest Therapeutics in the fourth quarter valued at $33,000. Finally, Sabby Management LLC bought a new position in shares of Tempest Therapeutics in the fourth quarter valued at about $513,000. 22.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Tempest Therapeutics news, CEO Matthew Angel bought 231,482 shares of Tempest Therapeutics stock in a transaction dated Tuesday, March 24th. The shares were acquired at an average cost of $2.16 per share, with a total value of $500,001.12. Following the acquisition, the chief executive officer directly owned 231,482 shares of the company’s stock, valued at $500,001.12. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 6.28% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.